XENT - インタ―セクトENT (Intersect ENT Inc.) インタ―セクトENT

 XENTのチャート


 XENTの企業情報

symbol XENT
会社名 Intersect ENT Inc. (インタ―セクトENT)
分野(sector) Health Care   ヘルスケア
産業(industry) Medical/Dental Instruments  
業種 医療機器_医療用品_ディストリビュ―タ―   医療関連(Health Care)
概要 事業概要 インターセクトENT(Intersect ENT Inc.)は商業段階の薬物設備会社である。同社は耳、鼻、喉(ENT)の状態の患者用の薬物を開発する。同社は治療剤の標的化および持続放出を可能にする生体吸収性インプラント技術を放出する薬物を開発する。標的薬物送達技術はENTの医師が患者ケアを管理できるように設計される。同社の製品は慢性副鼻腔炎の治療のために副鼻腔手術を受ける患者のPROPELおよびPROPELミニ薬物放出インプラントである。同社は慢性副鼻腔炎の治療の連続体で患者を治療するために、局所的な薬物送達を提供するように設計された生体吸収性のインプラント技術を放出する薬剤をベースにした製品ポートフォリオを構築する。同社は篩骨洞静脈手術後に使用されるPROPEL、および篩骨洞または前頭洞手術後に使用されるPROPEL Miniを販売する。   インタ―セクトENTは米国のヘルスケア機器メ―カ―。耳鼻咽喉関係の臨床医業界向けに副鼻腔炎治療用のインプラントを製造、販売する。主な製品には抗炎症剤を副鼻腔に直接投与する薬剤溶出型ステント「PROPEL」がある。米国で25件以上の特許を保有。本社はカリフォルニア州。   Intersect ENT is a global ear, nose and throat medical technology leader dedicated to transforming patient care. The Company's steroid releasing implants are designed to provide mechanical spacing and deliver targeted therapy to the site of disease. In addition, Intersect ENT is continuing to expand its portfolio of products based on the Company's unique localized steroid releasing technology and is committed to broadening patient access to less invasive and more cost-effective care. In October 2020, Intersect ENT acquired Fiagon AG Medical Technologies, a global leader in electromagnetic surgical navigation solutions with an expansive portfolio of ENT product offerings, including the VENSURE sinus balloon, that complement the Company's PROPEL® and SINUVA® sinus implants and extend its geographic reach.
本社所在地 1555 Adams Drive Menlo Park CA 94025 USA
代表者氏名 Lisa D. Earnhardt リサD.アーナート
代表者役職名 President Chief Executive Officer Director 社長兼最高経営責任者(CEO)
電話番号 +1 650-641-2100
設立年月日 37895
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数
url www.intersectent.com
nasdaq_url https://www.nasdaq.com/symbol/xent
adr_tso
EBITDA EBITDA(百万ドル) -17.67000
終値(lastsale) 28.38
時価総額(marketcap) 864299646.54
時価総額 時価総額(百万ドル) 855.16330
売上高 売上高(百万ドル) 102.86500
企業価値(EV) 企業価値(EV)(百万ドル) 750.26630
当期純利益 当期純利益(百万ドル) -17.70900
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Intersect ENT Inc revenues increased 15% to $51M. Net loss increased 15% to $10.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Selling general and administrative increase of 6% to $37.5M (expense) Stock-based Compensation in SGA increase of 42% to $5M (expense).

 XENTのテクニカル分析


 XENTのニュース

   The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck''s Keytruda On Track For More Label Expansions, Eliem Debuts  2021/08/10 11:55:36 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9) Adagio Therapeutics, Inc. (NASDAQ: ADGI ) (IPOed Friday) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Axonics, Inc. (NASDAQ: AXNX ) BioLife Solutions, Inc. (NASDAQ: BLFS ) (announced a deal to buy privately-held Sexton Biotech to expand cell and gene therapy tools portfolio) BioNTech SE (NASDAQ: BNTX ) (reacted to its quarterly results and raised vaccine sales forecast) Caribou Biosciences, Inc. (NASDAQ: CRBU ) (IPOed July 23) Cortexyme, Inc. (NASDAQ: CRTX ) (announced its second-quarter results) Cytokinetics, Incorporated (NASDAQ: CYTK ) Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Edwards Lifesciences Corporation (NYSE: EW ) Eli Lilly and Company (NYSE: LLY ) Impel NeuroPharma, Inc. (NASDAQ: IMPL ) (announced publication of positive Phase 3 data for migraine treatment) Intersect ENT, Inc.
   ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Intersect ENT, Inc.  2021/08/09 18:47:00 PR Newswire
NEW YORK, Aug. 9, 2021 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Intersect ENT, Inc. (NASDAQ: XENT) and its board of directors concerning the proposed acquisition of the company by Medtronic plc (NYSE: MDT). Stockholders will receive $28.25
   (XENT Alert) Johnson Fistel Investigates Proposed Sale of Intersect ENT; Is $28.25 a Fair Price?  2021/08/07 14:06:00 PR Newswire
SAN DIEGO, Aug. 7, 2021 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Intersect ENT, Inc. (NASDAQ: XENT) ("Intersect" or the "Company") breached their fiduciary duties in connection with the proposed sale of
   Why Intersect ENT Shot 12% Higher on Friday  2021/08/06 20:22:10 The Motley Fool
It''s official: A big peer is buying out the specialty medical device maker.
   SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Intersect ENT, Inc. Buyout  2021/08/06 17:59:00 Intrado Digital Media
WILMINGTON, Del., Aug. 06, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating Intersect ENT, Inc. (Intersect) (NASDAQ GM: XENT ) regarding possible breaches of fiduciary duties and other violations of law related to Intersects agreement to be acquired by Medtronic, Inc. Under the terms of the agreement, Intersects shareholders will receive $28.25 in cash for each share of Intersect common stock they own.
   (XENT Alert) Johnson Fistel Investigates Proposed Sale of Intersect ENT; Is $28.25 a Fair Price?  2021/08/07 14:06:00 PR Newswire
SAN DIEGO, Aug. 7, 2021 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Intersect ENT, Inc. (NASDAQ: XENT) ("Intersect" or the "Company") breached their fiduciary duties in connection with the proposed sale of
   Why Intersect ENT Shot 12% Higher on Friday  2021/08/06 20:22:10 The Motley Fool
It''s official: A big peer is buying out the specialty medical device maker.
   SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Intersect ENT, Inc. Buyout  2021/08/06 17:59:00 Intrado Digital Media
WILMINGTON, Del., Aug. 06, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating Intersect ENT, Inc. (Intersect) (NASDAQ GM: XENT ) regarding possible breaches of fiduciary duties and other violations of law related to Intersects agreement to be acquired by Medtronic, Inc. Under the terms of the agreement, Intersects shareholders will receive $28.25 in cash for each share of Intersect common stock they own.
   Intersect ENT Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Intersect ENT, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm XENT  2021/08/06 16:45:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Intersect ENT, Inc. (NASDAQ: XENT) to Medtronic plc for $28.25 per share is fair to Intersect ENT shareholders. Halper Sadeh encourages Intersect ENT shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Inters
   Medtronic Purchases Intersect ENT for $1.1B  2021/08/06 16:29:41 The Middle Market
Intersect is a medical technology company focused on global ear, nose, and throat care.
   Dr. Neil Hattangadi Joins Intersect ENT’s Board of Directors  2021/03/11 21:05:00 Business Wire
MENLO PARK, Calif.--(BUSINESS WIRE)--Dr. Neil Hattangadi Joins Intersect ENT’s Board of Directors
   Intersect ENT to Report Fourth Quarter and Full Year 2020 Financial Results  2021/02/23 21:05:00 Business Wire
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT to Report Fourth Quarter and Full Year 2020 Financial Results
   Intersect ENT Earnings Scorecard & Analyst Reports for Stock market Insights & financial analysis  2021/02/22 02:25:00 Stock Market Daily
Intersect ENT announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Intersect ENT Announces Launch of the New Straight Delivery System Packaged with the PROPEL® Mini Sinus Implant  2021/02/11 12:00:00 Business Wire
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced the U.S. availability of the new Straight Delivery System (“SDS”) packaged with the company’s PROPEL® Mini (mometasone furoate) Sinus Implant. The combined packaging of the SDS with PROPEL Mini received premarket approval (“PMA”) by the U.S. Food and Drug Administration (“FDA”) which follows PMA for the
   Intersect ENT to Participate in Upcoming Investor Conferences  2021/02/01 21:05:00 Business Wire
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT to Participate in Upcoming Investor Conferences

 関連キーワード  (医療機器_医療用品_ディストリビュ―タ― 米国株 インタ―セクトENT XENT Intersect ENT Inc.)

医療で使われる機器のこと。レントゲン装置やからだの断面を画像化できるMRI(磁気共鳴画像)装置など高機能機器を含め数多くの種類がある。医療現場で使われるため、正確で精密である点などが求められる。医療機器への需要は着実に高まっており、電機メーカーなどからの進出も進んでいる。

 twitter  (公式ツイッターやCEOツイッターなど)